APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocytes Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulocytes Antibody Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchGranulocytes Antibody Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocytes Antibody Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Granulocytes Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocytes Antibody Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocytes Antibody Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Granulocytes Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulocytes Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocytes Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocytes Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulocytes Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulocytes Antibody market include Thermo Fisher, RayBiotech, Inc., Boster Biological Technology, ZodelBiotec Ltd., MyBiosource, Inc., LifeSpan BioSciences, Inc, Innovative Research, CUSABIO and CLOUD-CLONE CORP., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Granulocytes Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocytes Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocytes Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Granulocytes Antibody market.

Granulocytes Antibody Segment by Company

Thermo Fisher

RayBiotech, Inc.

Boster Biological Technology

ZodelBiotec Ltd.

MyBiosource, Inc.

LifeSpan BioSciences, Inc

Innovative Research

CUSABIO

CLOUD-CLONE CORP.

Biomatik

Assay Genie

Abbexa

Granulocytes Antibody Segment by Type

Polyclonal Antibody

Monoclonal Antibody

Granulocytes Antibody Segment by Application

Western Blot

Flow Cytometry

ELISA

Immunoprecipitation

Immunofluorescence

Other

Granulocytes Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Granulocytes Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Granulocytes Antibody key companies, revenue, market share, and recent developments.

3. To split the Granulocytes Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Granulocytes Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulocytes Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze Granulocytes Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocytes Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocytes Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocytes Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocytes Antibody industry.

Chapter 3: Detailed analysis of Granulocytes Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Granulocytes Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Granulocytes Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulocytes Antibody Industry Trends Table 2. Granulocytes Antibody Industry Drivers Table 3. Granulocytes Antibody Industry Opportunities and Challenges Table 4. Granulocytes Antibody Industry Restraints Table 5. Global Granulocytes Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulocytes Antibody Revenue Share by Company (2021-2026) Table 7. Global Granulocytes Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Granulocytes Antibody Key Company Manufacturing Base & Headquarters Table 9. Global Granulocytes Antibody Company, Product Type & Application Table 10. Global Granulocytes Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Granulocytes Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Antibody Table 15. Significant Companies of Monoclonal Antibody Table 16. Global Granulocytes Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Granulocytes Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Granulocytes Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Granulocytes Antibody Sales Value Share by Type (2021-2026) Table 20. Global Granulocytes Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Flow Cytometry Table 23. Significant Companies of ELISA Table 24. Significant Companies of Immunoprecipitation Table 25. Significant Companies of Immunofluorescence Table 26. Significant Companies of Other Table 27. Global Granulocytes Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Granulocytes Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Granulocytes Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Granulocytes Antibody Sales Value Share by Application (2021-2026) Table 31. Global Granulocytes Antibody Sales Value Share by Application (2027-2032) Table 32. Global Granulocytes Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Granulocytes Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Granulocytes Antibody Sales Value Share by Region (2021-2026) Table 35. Global Granulocytes Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Granulocytes Antibody Sales Value Share by Region (2027-2032) Table 37. Global Granulocytes Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Granulocytes Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Granulocytes Antibody Sales Value Market Share by Country (2021-2026) Table 40. Global Granulocytes Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Granulocytes Antibody Sales Value Market Share by Country (2027-2032) Table 42. Thermo Fisher Company Information Table 43. Thermo Fisher Business Overview Table 44. Thermo Fisher Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Thermo Fisher Granulocytes Antibody Product Portfolio Table 46. Thermo Fisher Recent Development Table 47. RayBiotech, Inc. Company Information Table 48. RayBiotech, Inc. Business Overview Table 49. RayBiotech, Inc. Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. RayBiotech, Inc. Granulocytes Antibody Product Portfolio Table 51. RayBiotech, Inc. Recent Development Table 52. Boster Biological Technology Company Information Table 53. Boster Biological Technology Business Overview Table 54. Boster Biological Technology Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Boster Biological Technology Granulocytes Antibody Product Portfolio Table 56. Boster Biological Technology Recent Development Table 57. ZodelBiotec Ltd. Company Information Table 58. ZodelBiotec Ltd. Business Overview Table 59. ZodelBiotec Ltd. Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. ZodelBiotec Ltd. Granulocytes Antibody Product Portfolio Table 61. ZodelBiotec Ltd. Recent Development Table 62. MyBiosource, Inc. Company Information Table 63. MyBiosource, Inc. Business Overview Table 64. MyBiosource, Inc. Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. MyBiosource, Inc. Granulocytes Antibody Product Portfolio Table 66. MyBiosource, Inc. Recent Development Table 67. LifeSpan BioSciences, Inc Company Information Table 68. LifeSpan BioSciences, Inc Business Overview Table 69. LifeSpan BioSciences, Inc Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. LifeSpan BioSciences, Inc Granulocytes Antibody Product Portfolio Table 71. LifeSpan BioSciences, Inc Recent Development Table 72. Innovative Research Company Information Table 73. Innovative Research Business Overview Table 74. Innovative Research Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Innovative Research Granulocytes Antibody Product Portfolio Table 76. Innovative Research Recent Development Table 77. CUSABIO Company Information Table 78. CUSABIO Business Overview Table 79. CUSABIO Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CUSABIO Granulocytes Antibody Product Portfolio Table 81. CUSABIO Recent Development Table 82. CLOUD-CLONE CORP. Company Information Table 83. CLOUD-CLONE CORP. Business Overview Table 84. CLOUD-CLONE CORP. Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. CLOUD-CLONE CORP. Granulocytes Antibody Product Portfolio Table 86. CLOUD-CLONE CORP. Recent Development Table 87. Biomatik Company Information Table 88. Biomatik Business Overview Table 89. Biomatik Granulocytes Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Biomatik Granulocytes Antibody Product Portfolio Table 91. Biomatik Recent Development Table 92. Assay Genie Company Information Table 93. Assay Genie Business Overview Table 94. Assay Genie Granulocytes Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Assay Genie Granulocytes Antibody Product Portfolio Table 96. Assay Genie Recent Development Table 97. Abbexa Company Information Table 98. Abbexa Business Overview Table 99. Abbexa Granulocytes Antibody Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Abbexa Granulocytes Antibody Product Portfolio Table 101. Abbexa Recent Development Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Granulocytes Antibody Product Image Figure 2. Global Granulocytes Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocytes Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulocytes Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Antibody Image Figure 8. Monoclonal Antibody Image Figure 9. Global Granulocytes Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Granulocytes Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Granulocytes Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Flow Cytometry Image Figure 14. ELISA Image Figure 15. Immunoprecipitation Image Figure 16. Immunofluorescence Image Figure 17. Other Image Figure 18. Global Granulocytes Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Granulocytes Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Granulocytes Antibody Sales Value Share by Application (2021-2032) Figure 21. Global Granulocytes Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Granulocytes Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Granulocytes Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. North America Granulocytes Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Granulocytes Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Granulocytes Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Granulocytes Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Granulocytes Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Granulocytes Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. South America Granulocytes Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Granulocytes Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Granulocytes Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Granulocytes Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal Antibody
  • Monoclonal Antibody
Applications
  • Western Blot
  • Flow Cytometry
  • ELISA
  • Immunoprecipitation
  • Immunofluorescence
  • Other
Companies covered
  • Thermo Fisher
  • RayBiotech, Inc.
  • Boster Biological Technology
  • ZodelBiotec Ltd.
  • MyBiosource, Inc.
  • LifeSpan BioSciences, Inc
  • Innovative Research
  • CUSABIO
  • CLOUD-CLONE CORP.
  • Biomatik
  • Assay Genie
  • Abbexa

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulocytes Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulocytes Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Granulocytes Antibody Market Dynamics
  1. 2.1 Granulocytes Antibody Industry Trends
  2. 2.2 Granulocytes Antibody Industry Drivers
  3. 2.3 Granulocytes Antibody Industry Opportunities and Challenges
  4. 2.4 Granulocytes Antibody Industry Restraints
3 Granulocytes Antibody Market by Company
  1. 3.1 Global Granulocytes Antibody Company Revenue Ranking in 2025
  2. 3.2 Global Granulocytes Antibody Revenue by Company (2021-2026)
  3. 3.3 Global Granulocytes Antibody Company Ranking (2024-2026)
  4. 3.4 Global Granulocytes Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global Granulocytes Antibody Company Product Type and Application
  6. 3.6 Global Granulocytes Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Granulocytes Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Granulocytes Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Granulocytes Antibody Market by Type
  1. 4.1 Granulocytes Antibody Type Introduction
  2. 4.1.1 Polyclonal Antibody
  3. 4.1.2 Monoclonal Antibody
  4. 4.2 Global Granulocytes Antibody Sales Value by Type
  5. 4.2.1 Global Granulocytes Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Granulocytes Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global Granulocytes Antibody Sales Value Share by Type (2021-2032)
5 Granulocytes Antibody Market by Application
  1. 5.1 Granulocytes Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Flow Cytometry
  4. 5.1.3 ELISA
  5. 5.1.4 Immunoprecipitation
  6. 5.1.5 Immunofluorescence
  7. 5.1.6 Other
  8. 5.2 Global Granulocytes Antibody Sales Value by Application
  9. 5.2.1 Global Granulocytes Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Granulocytes Antibody Sales Value by Application (2021-2032)
  11. 5.2.3 Global Granulocytes Antibody Sales Value Share by Application (2021-2032)
6 Granulocytes Antibody Regional Value Analysis
  1. 6.1 Global Granulocytes Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocytes Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global Granulocytes Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global Granulocytes Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulocytes Antibody Sales Value (2021-2032)
  7. 6.3.2 North America Granulocytes Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Granulocytes Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe Granulocytes Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Granulocytes Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Granulocytes Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Granulocytes Antibody Sales Value (2021-2032)
  16. 6.6.2 South America Granulocytes Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Granulocytes Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Granulocytes Antibody Sales Value Share by Country, 2025 VS 2032
7 Granulocytes Antibody Country-level Value Analysis
  1. 7.1 Global Granulocytes Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulocytes Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global Granulocytes Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global Granulocytes Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Granulocytes Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Granulocytes Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Granulocytes Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher
  2. 8.1.1 Thermo Fisher Company Information
  3. 8.1.2 Thermo Fisher Business Overview
  4. 8.1.3 Thermo Fisher Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Granulocytes Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Recent Developments
  7. 8.2 RayBiotech, Inc.
  8. 8.2.1 RayBiotech, Inc. Company Information
  9. 8.2.2 RayBiotech, Inc. Business Overview
  10. 8.2.3 RayBiotech, Inc. Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 RayBiotech, Inc. Granulocytes Antibody Product Portfolio
  12. 8.2.5 RayBiotech, Inc. Recent Developments
  13. 8.3 Boster Biological Technology
  14. 8.3.1 Boster Biological Technology Company Information
  15. 8.3.2 Boster Biological Technology Business Overview
  16. 8.3.3 Boster Biological Technology Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boster Biological Technology Granulocytes Antibody Product Portfolio
  18. 8.3.5 Boster Biological Technology Recent Developments
  19. 8.4 ZodelBiotec Ltd.
  20. 8.4.1 ZodelBiotec Ltd. Company Information
  21. 8.4.2 ZodelBiotec Ltd. Business Overview
  22. 8.4.3 ZodelBiotec Ltd. Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ZodelBiotec Ltd. Granulocytes Antibody Product Portfolio
  24. 8.4.5 ZodelBiotec Ltd. Recent Developments
  25. 8.5 MyBiosource, Inc.
  26. 8.5.1 MyBiosource, Inc. Company Information
  27. 8.5.2 MyBiosource, Inc. Business Overview
  28. 8.5.3 MyBiosource, Inc. Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MyBiosource, Inc. Granulocytes Antibody Product Portfolio
  30. 8.5.5 MyBiosource, Inc. Recent Developments
  31. 8.6 LifeSpan BioSciences, Inc
  32. 8.6.1 LifeSpan BioSciences, Inc Company Information
  33. 8.6.2 LifeSpan BioSciences, Inc Business Overview
  34. 8.6.3 LifeSpan BioSciences, Inc Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LifeSpan BioSciences, Inc Granulocytes Antibody Product Portfolio
  36. 8.6.5 LifeSpan BioSciences, Inc Recent Developments
  37. 8.7 Innovative Research
  38. 8.7.1 Innovative Research Company Information
  39. 8.7.2 Innovative Research Business Overview
  40. 8.7.3 Innovative Research Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Innovative Research Granulocytes Antibody Product Portfolio
  42. 8.7.5 Innovative Research Recent Developments
  43. 8.8 CUSABIO
  44. 8.8.1 CUSABIO Company Information
  45. 8.8.2 CUSABIO Business Overview
  46. 8.8.3 CUSABIO Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CUSABIO Granulocytes Antibody Product Portfolio
  48. 8.8.5 CUSABIO Recent Developments
  49. 8.9 CLOUD-CLONE CORP.
  50. 8.9.1 CLOUD-CLONE CORP. Company Information
  51. 8.9.2 CLOUD-CLONE CORP. Business Overview
  52. 8.9.3 CLOUD-CLONE CORP. Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CLOUD-CLONE CORP. Granulocytes Antibody Product Portfolio
  54. 8.9.5 CLOUD-CLONE CORP. Recent Developments
  55. 8.10 Biomatik
  56. 8.10.1 Biomatik Company Information
  57. 8.10.2 Biomatik Business Overview
  58. 8.10.3 Biomatik Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biomatik Granulocytes Antibody Product Portfolio
  60. 8.10.5 Biomatik Recent Developments
  61. 8.11 Assay Genie
  62. 8.11.1 Assay Genie Company Information
  63. 8.11.2 Assay Genie Business Overview
  64. 8.11.3 Assay Genie Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Assay Genie Granulocytes Antibody Product Portfolio
  66. 8.11.5 Assay Genie Recent Developments
  67. 8.12 Abbexa
  68. 8.12.1 Abbexa Company Information
  69. 8.12.2 Abbexa Business Overview
  70. 8.12.3 Abbexa Granulocytes Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Abbexa Granulocytes Antibody Product Portfolio
  72. 8.12.5 Abbexa Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst